Research
Hormonal
Dietary cholesterol is a distinct and critical risk factor for the progression of NAFLD to NASH, driving inflammation and oxidative stress independently of total lipid accumulation.
For those with fatty liver, paying attention to dietary cholesterol intake may be important for preventing progression to more severe liver disease (NASH). This includes limiting high-cholesterol foods, as the liver's ability to handle cholesterol is compromised in NAFLD, leading to inflammation.
GoodSupportsHIGH confidence
Wouters et al. [124] found that dietary cholesterol rather than lipid accumulation is an important risk factor for the progression to hepatic inflammation. High-cholesterol diet led to increased VLDL and was sufficient to cause inflammatory response in the liver.
Why this rating
Supported by multiple studies cited in the review, including metabolomic analysis and rodent models.
Source
Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
Klementina Fon Tacer et al. · Journal of Lipids · 2011
DOI 10.1155/2011/783976
narrative_reviewCited 232×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance drives NAFLD pathogenesis through two main mechanisms: increased adipose tissue lipolysis (free fatty acid overflow) and increased hepatic de novo lipogenesis (fatty acid synthesis), leading to triglyceride accumulation.Strong
- In the context of Nonalcoholic Fatty Liver Disease (NAFLD), hepatic triglyceride accumulation acts as a hepatoprotective buffering mechanism against lipotoxicity; inhibiting triglyceride synthesis (e.g., via DGAT2 inhibition) exacerbates liver damage and fibrosis despite reducing steatosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →